Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-1956524900.0%
operating margin TTM
-2006394100.0%
revenue TTM
2.92 Million
revenue per share TTM
0.04$
valuation ratios | |
|---|---|
| pe ratio | -0.98 |
| peg ratio | -0.14 |
| price to book ratio | -36.16 |
| price to sales ratio | 149,822,784.00 |
| enterprise value multiple | -7.52 |
| price fair value | -36.16 |
profitability ratios | |
|---|---|
| gross profit margin | -1970400.0% |
| operating profit margin | -2006394100.0% |
| pretax profit margin | -1956524900.0% |
| net profit margin | -1956524900.0% |
| return on assets | -447.01% |
| return on equity | -350.62% |
| return on capital employed | 3781.43% |
liquidity ratio | |
|---|---|
| current ratio | 0.85 |
| quick ratio | 0.85 |
| cash ratio | 0.19 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 46,849.29 |
| cash conversion cycle | -46,849.29 |
| receivables turnover | 0.00 |
| payables turnover | 0.01 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.03 |
| debt equity ratio | -0.27 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | -0.38 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -118.76 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.94 |
| cash per share | 0.37 |
| operating cash flow per share | -1.94 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -118.76 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -1,211.19 |
Frequently Asked Questions
When was the last time Inhibikase Therapeutics, Inc. (NASDAQ:IKT) reported earnings?
Inhibikase Therapeutics, Inc. (IKT) published its most recent earnings results on 14-11-2024.
What is Inhibikase Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Inhibikase Therapeutics, Inc. (NASDAQ:IKT)'s trailing twelve months ROE is -350.62%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Inhibikase Therapeutics, Inc. (IKT) currently has a ROA of -447.01%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did IKT's net profit margin stand at?
IKT reported a profit margin of -1956524900.0% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is IKT's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 0.85 in the most recent quarter. The quick ratio stood at 0.85, with a Debt/Eq ratio of -0.27.